Intra-Cellular Therapies announces initiation of ITI-007-201 phase 3 clinical trial
Intra-Cellular Therapies announced the Company has initiated Phase 3 development of ITI-007 for the treatment of agitation in patients with dementia, including Alzheimer's disease. The ‘201 trial is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial. June 28, 2016